Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693802 | 0.89 | ALDH1A1 (0.55) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL693864 | 0.89 | ALDH1A1 (0.54) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL15197213 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL698319 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL693105 | 0.86 | ALDH1A1 (0.51) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3108469 | 0.85 | ALDH1A1 (0.53) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL697681 | 0.85 | ALDH1A1 (0.56) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL692992 | 0.84 | ALDH1A1 (0.52) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL694947 | 0.84 | ALDH1A1 (0.44) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL694152 | 0.84 | ALDH1A1 (0.54) | MAPTALDH1A1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727908-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8669247-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669247-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8399456-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399456-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2010123956-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225565-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | MAPT 3430/4885ALDH1A1 1818/4885KMT2A 2549/4885 |
| US-20100273782-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | MAPT 3430/4885ALDH1A1 1818/4885KMT2A 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.